Evommune (EVMN) Q2 2026 earnings summary

Executive summary

• Focused on developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 in Phase 2 development for indications including atopic dermatitis, migraine, and ulcerative colitis.

• Ceased development of EVO756 for chronic spontaneous urticaria after Phase 2b trial failed to meet its primary endpoint; ongoing trials continue in other indications.

• Announced upcoming Phase 2b top-line data for EVO756 in atopic dermatitis in September 2026 and initiated a Phase 2b trial for migraine prophylaxis with data expected in 2027.

• Positive Phase 2a data for EVO301 in atopic dermatitis to be presented at a medical conference, supporting a planned Phase 2b trial in mid-2027.

• Strong cash position expected to fund operations and key data readouts through 2028.

Financial highlights

• Net loss of $32.2 million for Q2 2026, compared to $13.6 million in Q2 2025; net loss of $53.9 million for the six months ended June 30, 2026, versus $28.1 million for the same period in 2025.

• Cash, cash equivalents, and investments totaled $288.0 million as of June 30, 2026, up from $217 million at year-end 2025.

• No revenue recognized in the first half of 2026; $3.0 million in non-recurring license revenue recognized in the first half of 2025.

• Research and development expenses rose to $43.7 million for the first half of 2026, up from $34.0 million year-over-year, with Q2 2026 R&D expenses at $26.4 million.

• General and administrative expenses increased to $15.1 million for the first half of 2026, up from $7.0 million year-over-year, with Q2 2026 G&A expenses at $8.5 million.

Outlook and guidance

• Cash runway expected to fund operations and clinical milestones through 2028 based on current business plan.

• Top-line Phase 2b data for EVO756 in atopic dermatitis expected in September 2026; migraine prophylaxis trial underway with data anticipated in 2027.

• EVO301 Phase 2b atopic dermatitis trial planned for mid-2027, pending manufacturing and toxicology completion.

• Anticipates continued increases in R&D and G&A expenses as clinical programs advance and company infrastructure grows.

• Expects to require substantial additional funding for further development and commercialization efforts; no product revenue expected for several years.